Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Surgical vs. trans-catheter aortic valve replacement in patients With bicuspid aortic valve stenosis.

Frontiers in cardiovascular medicine·2026

Same author

Substantial early morbidity and incomplete left ventricular recovery in Takotsubo syndrome: A single-center cohort study.

International journal of cardiology·2026

Same author

Safety and Feasibility of a CT-Based Pathway for Left Atrial Appendage Assessment Prior to Inpatient Cardioversion: A Single-Center Experience.

Clinical cardiology·2026

Same author

Impact of routine urine sodium evaluation on diuretic practices in patients with acute heart failure.

ESC heart failure·2026

Same author

Residual perfusion defects after acute pulmonary embolism: Prevalence, determinants, and clinical impact.

The American journal of medicine·2026

Same author

Clinical Features and Outcomes of Acute Myocarditis in Patients with Swab-Confirmed Respiratory Viral Pathogens.

The Israel Medical Association journal : IMAJ·2026

Search research articles

Related Experiment Videos

Clopidogrel resistance--the cardiologist's perspective.

Paul Fefer¹, Hanoch Hod, Shlomi Matetzky

¹Heart Institute, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Tel Aviv University, Israel. paul.fefer@sheba.health.gov.il

|May 15, 2007

Summary

Clopidogrel resistance contributes to cardiovascular events in patients with acute coronary syndromes despite treatment. This review clarifies current knowledge on clopidogrel resistance and its impact.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology
Thrombosis

Background:

Platelet activation and aggregation are key in acute coronary syndromes (ACS) pathogenesis.
Clopidogrel reduces atherothrombotic events post-percutaneous coronary intervention (PCI) and in ACS.
A significant number of patients experience recurrent cardiovascular events despite clopidogrel therapy.

Purpose of the Study:

To review and clarify current understanding of clopidogrel resistance.
To explore the link between clopidogrel resistance and treatment failure in ACS patients.

Main Methods:

Literature review of studies on clopidogrel resistance.
Analysis of factors contributing to antiplatelet treatment failure.

Main Results:

Evidence suggests clopidogrel resistance is a factor in treatment failure.
Understanding resistance mechanisms is crucial for optimizing therapy.

Conclusions:

Clopidogrel resistance is a significant clinical issue in acute coronary syndromes.
Further research is needed to address and overcome clopidogrel resistance for improved patient outcomes.